BioSpace News Archive

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September.

Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced the U.S. Food and Drug Administration has granted Fast Track Designation to Lomecel-B™ for the treatment of Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect affecting approximately 1,000 infants per year.

X4 Pharmaceuticals, Inc. announced that it will host an investor webinar to present and discuss new data from its Phase 1b trial evaluating its lead clinical candidate, mavorixafor, in patients with idiopathic, cyclic, and congenital neutropenia.

Vaxart, Inc. announced that it has named Ray Stapleton, Ph.D., as its Chief Technology Officer, effective immediately.

Blue Water Vaccines Inc. announced that Joseph Hernandez, Chairman and Chief Executive Officer, will present at H.C. Wainwright’s 24th Annual Global Investment Conference, held from September 12-14, 2022, in New York, NY.

Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).

SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that effective August 26, 2022, it has granted an aggregate of 2,877,500 stock options to certain employees and officers of the Company under the Company’s amended and restated stock option plan.

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that management will participate at Citi’s 17th Annual BioPharma Conference.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MZE001, the company’s investigational product for the treatment of Pompe disease.